Oruka Therapeutics Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (685,276 versus 3,438,781). Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Tango Therapeutics Inc. for 0 Days on average.
| ORKA | TNGX | |
|---|---|---|
Market Cap | $5.08B | $3.74B |
Volume | 685,276 | 3,438,781 |
Sector | Health | Health |
52-Week High | $113.08 | $32.90 |
52-Week Low | $26.19 | $7.50 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.21B | $2.76B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →